APOKYN (apomorphine)

INITIATION DOSE IS OFFICE ADMINISTERED: SUBCUTANEOUS INJECTION

Indication(s) for Prior Authorization:

  • Parkinson’s Disease, treatment of hypomobility

Patients must meet all the following criteria for the indication above:

  • Adjunctive treatment for patients with advanced Parkinson’s Disease experiencing acute hypomobility secondary to end-of-dose wearing off  episodes or unpredictable off  episodes
  • Prescribed or recommended by a neurologist
  • Must be on concurrent therapy with: carbidopa-levodopa (Sinemet ®) at the maximum tolerated dose and a second agent such as a MAO-B inhibitor, Dopamine Agonist or COMT inhibitor
  • Concurrent therapy with trimethobenzamide (Tigan) – 3 days prior to initiation and continued for at least 2 months after apomorphine
  • Contraindicated in patients who are currently taking 5HT3 antagonists

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Any Indication not listed above

Dosing:

  • Up to 0.6 ml (6 mg) subcutaneously

 

Last review date: December 1, 2014

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone